Antibody response to hepatitis B vaccine in substance use disorder patients.
The objectives of this study were to assess the prevalence of prognostic factors previously known to be associated with poor antibody response to hepatitis B vaccination in a sample of veterans presenting for substance use disorders treatment at a Veterans Health Administration (VA) Medical Center, assess vaccination response, and identify markers for poor response in this population. Results indicated that most participants had multiple prognostic factors previously known to be associated with poor antibody response including male gender, age over 40, smoking, and obesity. The rate of seroconversion in this sample was 51.9%. This is substantially lower than seen in healthy adults. Alcohol dependence was the only significant independent negative predictor of seroconversion in this sample. Substance use disorders treatment providers who are considering adding hepatitis B vaccination services to their clinics should be aware that the antibody response to the hepatitis B vaccination is inconsistent and that patients with particular demographic characteristics may be at heightened risk of poor antibody response.
Hagedorn
Hildi J
HJ
Veterans Health Administration's Substance Use Disorders Quality Enhancement Research Initiative, Minneapolis VA Medical Center, Minneapolis, MN 55417, USA. hildi.hagedorn@va.gov
Rettmann
Nancy A
NA
Dieperink
Eric W
EW
Durfee
Janet
J
Aqel
Bashar
B
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D005260:Female; D006510:Hepatitis B Antibodies / Q000097:blood*; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D011379:Prognosis; D016036:Seroepidemiologic Studies; D019966:Substance-Related Disorders / Q000097:blood / Q000276:immunology*; D014728:Veterans / Q000706:statistics & numerical data
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines